Global cephalosporin drugs market projected to rise 3.34 percent
Posted: 19 August 2019 | Victoria Rees (European Pharmaceutical Review) | No comments yet
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
The global cephalosporin drugs market is expected to increase at a compound annual growth rate (CAGR) of 3.34 percent in the forecast period to 2025, according to a report.
The trade of the semi-synthetic, wide-spectrum antibiotics is predicted to reach $14.1 billion by the end of the forecast period.
The research, conducted by Reportlinker, suggests that increasing incidences of pneumonia, tonsillitis, bronchitis and gonorrhoea are the main variables contributing to market growth.
Increasing R&D operations to create extremely effective and secure medicines as well as increasing the use of combination therapies further enhance the growth of the market.
…increasing incidences of pneumonia, tonsillitis, bronchitis and gonorrhoea are the main variables contributing to market growth
However, the growth is reportedly restricted due to the side effects of cephalosporin drugs and the development of drug-resistant bacterial strains.
Key players in the industry include Bayer AG, Teva Pharmaceuticals and GlaxoSmithKline (GSK).
Related topics
Related organisations
Bayer AG, GlaxoSmithKline (GSK), Reportlinker, Teva Pharmaceuticals
